Literature DB >> 10404067

Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice.

K Chikamatsu1, T E Reichert, Y Kashii, T Saito, S Kawashiri, E Yamamoto, T L Whiteside.   

Abstract

We have previously reported that immune anti-tumor effector cells, both cytotoxic T lymphocytes (CTLs) and IL-2-activated natural killer (A-NK) cells, are effective at eliminating human head-and-neck cancer (HNC) targets in vitro and in vivo in xenograft models. In this study, these 2 types of human effector cell were compared for the ability to prevent the development of lymph node metastases in a metastasis model of human squamous-cell carcinoma of the head and neck (SCCHN) established in nude mice. A tumor cell line, OSC-19, was injected into the floor of the mouth in nude mice, and the tumor grew progressively and metastasized to cervical lymph nodes by day 21. As effector cells, a human HLA-A2-restricted CTL line recognizing a shared antigen on OSC-19 and human non-MHC-restricted A-NK cells were used. Both types of effector cell mediated high levels of lysis against OSC-19 targets in 4-hr (51)Cr-release assays. Administration of human CTLs or A-NK cells and IL-2 to the site of tumor growth in mice with 7-day OSC-19 tumors resulted in significant reduction of the number of lymph node metastases relative to untreated or sham-operated controls or to mice treated with IL-2 without the effector cells. Our results suggest that in a xenograft model of human SCCHN implanted in the oral cavity of nude mice, the development of lymph node metastases can be successfully controlled by adoptive transfer of human SCCHN-specific CTLs or SCCHN-reactive A-NK cells plus IL-2. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10404067     DOI: 10.1002/(sici)1097-0215(19990812)82:4<532::aid-ijc11>3.0.co;2-g

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Suppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancer.

Authors:  Dejan Baskic; Lazar Vujanovic; Nebojsa Arsenijevic; Theresa L Whiteside; Eugene N Myers; Nikola L Vujanovic
Journal:  Head Neck       Date:  2012-04-05       Impact factor: 3.147

Review 2.  Immunobiology and immunotherapy of head and neck cancer.

Authors:  T L Whiteside
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

Review 3.  Advantages and clinical applications of natural killer cells in cancer immunotherapy.

Authors:  Erik Ames; William J Murphy
Journal:  Cancer Immunol Immunother       Date:  2013-08-30       Impact factor: 6.968

4.  Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.

Authors:  P Radny; U M Caroli; J Bauer; T Paul; C Schlegel; T K Eigentler; B Weide; M Schwarz; C Garbe
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.